Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2023 09:05 ET | Source: Affimed N.V.

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a...
November 01, 2023 06:30 ET | Source: Affimed N.V.

Affimed to Participate in Upcoming Investor Conferences

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
October 04, 2023 06:30 ET | Source: Affimed N.V.

Affimed Announces Listing Transfer to Nasdaq Capital Markets

MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
September 27, 2023 09:05 ET | Source: Affimed N.V.

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
September 21, 2023 06:30 ET | Source: Affimed N.V.

Affimed to Present at the Cantor Global Healthcare Conference 2023

MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
September 12, 2023 06:30 ET | Source: Affimed N.V.

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the...
September 07, 2023 06:30 ET | Source: Affimed N.V.

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
August 22, 2023 05:00 ET | Source: Affimed N.V.

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’ serum half-life with FcRn column dissociation...
August 10, 2023 06:30 ET | Source: Affimed N.V.

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

AFM13 combination with AB-101 NK cells (LuminICE-203): On track to report initial efficacy and safety data in the first half 2024; Type C meeting request submitted to FDA to clarify requirements for...
August 03, 2023 06:30 ET | Source: Affimed N.V.

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...